Singapore, 8 December 2025 — ChemLex, a next-generation AI-for-science company, recently announced the establishment of its global headquarters in Singapore, alongside the close of a USD 45 million funding led by Granite Asia. Other investors in this round include Qiming Venture Partners, LYFE Capital, and Sinovation Ventures.

ChemLex integrates proprietary AI algorithms with high-throughput robotic systems capable of designing, synthesising, and analysing molecules around the clock. By coupling data-driven retrosynthesis prediction with real-time feedback and automated experimentation, ChemLex shortens the discovery-to-delivery cycle for pharmaceutical and biotech partners while reducing energy consumption and waste.

The new capital will accelerate ChemLex’s development of its AI-powered, fully automated chemical synthesis system, positioning the company at the forefront of a global movement to digitise and automate scientific discovery for the pharmaceutical industry. The facility anchors ChemLex’s international R&D network, strengthening collaborations with Singapore's vibrant drug discovery ecosystem, leading biopharma companies and academia. Advancing a shared mission together: to make chemistry faster, smarter, and greener through artificial intelligence and automation.

This round builds on ChemLex’s earlier USD 26 million Series A financing, co-led by Qiming Venture Partners and LYFE Capital, which enabled rapid R&D progress, early commercial partnerships, and expansion into international markets. With the new Series A+ investment, ChemLex will further strengthen its Singapore operations by advancing automation development and scaling its AI-for-Science platform to support global clients.

ChemLex also signed a memorandum of understanding (MOU) with the Experimental Drug Development Centre (EDDC), Singapore’s national platform for drug discovery and development hosted by the Agency for Science, Technology and Research (A*STAR). This collaboration seeks to accelerate next-generation small molecule drug discovery through advanced automation.

Sean Lin, Founder and CEO of ChemLex, “We’re building an R&D engine that significantly accelerates organic synthesis, transforming both the speed and efficiency of drug discovery. Singapore strengthens this effort and provides us an ecosystem to scale rapidly and support partners globally who need this capability now.”

Yinghui Kuang, Partner at Granite Asia, “AI-driven science is reshaping industries from pharmaceuticals to materials. ChemLex sits in that sweet spot, combining artificial intelligence, robotics, and chemistry to deliver scalable results that can redefine how molecules are discovered and made. We believe Singapore provides the ideal ecosystem for this transformation.”

Goh Wan Yee, Senior Vice President and Head, Healthcare, Economic Development Board: “ChemLex’s decision to anchor its global R&D headquarters and AI laboratory in Singapore reflects how companies can leverage the confluence of our strengths in deep tech and biomedical sciences ecosystem, to launch breakthrough innovations. We look forward to supporting more like-minded partners like ChemLex, to accelerate scientific discoveries that will benefit patients worldwide.”

Prof. Damian O'Connell of the Experimental Drug Development Centre said “We first met ChemLex in 2023, and since then we’ve seen the company grow from a promising startup to a global innovator in AI and automation-driven chemical synthesis. As ChemLex’s first Singapore partner, we are thrilled to expand our collaboration through the MOU. This partnership reinforces our shared vision of accelerating drug discovery and development through cutting-edge technology, ultimately bringing safer, more effective therapies to patients faster. By combining EDDC’s drug development expertise with ChemLex’s automation and AI capabilities, we aim to shorten timelines, reduce costs, and deliver innovative treatments that improve lives in Singapore locally and globally.”

About ChemLex

ChemLex is a Singapore-headquartered innovation company pioneering the integration of artificial intelligence, automation, and chemical synthesis to accelerate global R&D. Its proprietary AI-for-Chemistry platform and autonomous synthesis systems enable 24/7 high-throughput experimentation that shortens discovery cycles and reduces costs across the pharmaceutical and biotech sectors.

For more information, visit chemlex.com